Not all FTSE shares are created equal. Some will drift sideways for years. Others could quietly compound into something extraordinary.
According to research by AJ Bell, 63% of all active analyst ratings on UK stocks are currently set to Buy – the most bullish institutional sentiment seen in over a decade. So even with markets near record highs, the experts clearly see plenty of opportunity ahead.
Here are three of their highest-conviction picks.
1. RELX: the data giant
RELX (LSE:REL) is a global information analytics company providing data, tools, and decision support across legal, scientific, medical, and financial sectors.
The long-term bull case is built on RELX’s extraordinary pricing power. Its customers are usually law firms, hospitals, and research institutions that are deeply embedded in RELX’s platforms and have very few credible alternatives. That kind of moat is exceptionally hard to replicate.
The bear case? Some worry that the rapid rise of artificial intelligence (AI) could gradually erode this moat by directly attacking the value proposition of the group’s proprietary datasets. After all, cheaper third-party tools can do a similar job, so why would customers pay a premium?
Luckily, so far, that narrative hasn’t proven to be true, but it’s nonetheless still a risk.
2. AstraZeneca: the global pharma titan powering ahead
AstraZeneca‘s (LSE:AZN) one of the world’s leading pharmaceutical companies, with a blockbuster pipeline spanning oncology, cardiovascular disease, and rare conditions.
Analysts at Citigroup, Barclays, and JP Morgan are all firmly in the Buy camp, with 81% of covering analysts recommending the stock. Why? Because the company might have one of the most impressive drug pipelines in the industry, with multiple late-stage trials that could unlock significant new revenue streams over the coming decade.
Of course, that doesn’t mean success is guaranteed. Drug development is exceptionally expensive and uncertain. And pipeline failures or pricing pressure from government healthcare systems could disappoint investors who’ve priced in significant success.
3. Beazley: the specialist insurer flying under the radar
Beazley (LSE:BEZ) is one of Lloyd’s of London’s leading specialist insurers, covering complex risks including cyber threats, marine, property, and professional indemnity across global markets.
Today, the company’s riding two powerful tailwinds. First, cyber insurance is one of the fastest growing segments in the entire insurance industry. And Beazley’s already recognised as a market leader with deep underwriting expertise that competitors struggle to replicate quickly.
The second tailwind is the higher-for-longer interest rate environment. Thanks to increased income from bonds and other short-duration fixed-income instruments, Beazley’s significant investment portfolio is already generating materially better returns than in previous years. And combined, these factors are boosting profitability from two directions at once.
But like all investments, there are risks to consider, most notably the inherently unpredictable nature of the specialist insurance business.
A major catastrophe or an unexpected surge in cyber claims could result in significant and sudden losses that pressure both the balance sheet and the share price.
The bottom line
These are three very different businesses, but all share a common thread: institutional analysts back them with rare conviction.
For investors wondering which FTSE shares to buy and hold through whatever the next decade brings, this trio looks like a compelling place to start investigating further. But they’re not the only opportunities I’ve got my eye on right now.
